Novartis Halts Fabhalta Trial for Lupus Nephritis

Key Facts

Novartis has terminated a mid-stage clinical trial of its drug Fabhalta specifically targeting lupus nephritis. Reuters reported that the company decided to discontinue the study of the drug, also known as iptacopan, before its planned completion. No specific efficacy or safety data triggering the termination were disclosed in the reports.

NVSEF closed at $144.32 on October 15, 2026, having reached a session high of $153.92. While Fabhalta maintains approvals for other medical indications, the discontinuation of the lupus nephritis trial impacts the company's research and development outlook within its renal and immunological pipeline.